Continuing Erythropoietin During Peripheral Blood Stem Cell Collection in Myeloma: Can It Reduce Toxicity of Autologous Transplants?

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1, 2008, Pages 132-133

  Labonté, Laura ^a   Iqbal, Tariq ^a   McDiarmid, Sheryl ^a   Bence Bruckler, Isabelle ^a   Huebsch, Lothar ^a   Allan, David ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COHORT ANALYSIS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INFORMED CONSENT; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPHIL COUNT; PERIPHERAL BLOOD STEM CELL; STEM CELL MOBILIZATION; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 37349021414     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.09.010     Document Type: Letter

References (10)

1. Prutchi-Sagiv S., Golishevsky N., Oster H.S., et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?. Br J Haem 135 (2006) 660-672
2. Bohlius J., Weingart O., Trelle S., et al. Cancer-related anemia and recombinant human erythropoietin: an updated overview. Nat Clin Pract Oncol 3 (2006) 152-164
3. Brines M., and Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70 (2006) 246-250
4. Crawford J. Recombinant human erythropoietin in cancer-related anemia: review of clinical evidence. Oncology 16 (2002) 41-53
5. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 (2002) 4083-4107
6. Mittelman M., Zeidman A., Kanter P., et al. Erythropoietin has an anti-myeloma effect: a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 72 (2004) 155-165
7. Xenocostas A., Yee A., Wong C.J., et al. RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival. Transfusion 43 (2003) 373-382
8. Al-Gahtani F., Tay J., Kasbia G., et al. Anemia of day of harvesting mobilized peripheral blood progenitors independently associated with increased toxicity after autologous hematopoietic transplantation. Bone Marrow Transplant 39 (2007) S311
9. Hunault-Berger M., Tanguy-Schmidt A., Rachieru P., et al. rHuEpo before high-dose therapy allows autologous peripheral stem cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant 35 (2005) 903-907
10. Iqbal T., Rajagopal T., Halpenny M., et al. Reinfusing stem cell grafts with increased vascular progenitors reduces tissue injury caused by high-dose chemotherapy in hematopoietic transplantation. Arterioscler Thromb Vasc Biol 27 (2007) e71